Opioid-free general anesthesia in patient with Steinert syndrome (myotonic dystrophy)

Case report

Tomasz Gaszynski, MD, PhD *

Abstract

Introduction: We report on the anesthetic management using opioid-free method of a patient with Steinert syndrome (myotonic dystrophy, MD), autosomal dominant dystrophy which is characterized by consistent contracture of muscle following stimulation. A myotonic crisis can be induced by numerous factors including hypothermia, shivering, and mechanical or electrical stimulation. In patients with MD, hypersensitivity to anesthetic drugs, especially muscle relaxants and opioids, may complicate postoperative management. If opioids are employed (systemic or neuraxial), then ICU care and continuous pulse oximetry must be considered given the high risk for respiratory depression and aspiration. Patients with MD present high sensitivity to the usual anesthetics such as volatile and muscle relaxants (both depolarizing and nondepolarizing). Opioids may induce muscle rigidity in this type of MD. Therefore, omitting opioids is recommended. Due to hypersensitivity to opioids and increased susceptibility to intra- and postoperative complications, it is recommended to introduce opioid-free anesthesia (OFA), for example, with use of dexmedetomidine (DEX). This is a new method of conducting general anesthesia without opioids and is based on concept of multimodal approach to pain management.

Methods: A 31-year-old male patient (183 cm, 69 kg) was scheduled for laparoscopic operation of cholecystectomy. The patient received intravenously (IV): propofol in a dose of 250 mg followed by continuous infusion, rocuronium in a dose of 20 mg, and DEX in a loading dose of 0.6 μg/kg over 10 minutes followed by continuous infusion of dose of 0.2 μg/kg/hour.

Results: The course of anesthesia and postoperative period were uneventful. The patient exited the operating theatre in a good medical state, with vitals within normal limits and fully regained consciousness.

Conclusion: DEX is effective and safe for moderately painful procedures in patients with the elevated risk of respiratory and cardiovascular failure. This substance provides adequate analgesia level during surgeries of patients suffering from MD.

Abbreviations: CPAP = continuous positive airway pressure, DEX = dexmedetomidine, MD = myotonic dystrophy, NSAIDs = Non-steroid anti-inflammatory drugs, OFA = opioid-free anesthesia.

Keywords: dexmedetomidine, general anesthesia, myotonic dystrophy, opioid-free anesthesia

1. Introduction

We report on the anesthetic management using opioid-free method of a patient with Steinert syndrome (myotonic dystrophy, MD), autosomal dominant dystrophy which is characterized by consistent contracture of muscle following stimulation. An abnormal nucleotide sequence on chromosome-19 causes prolonged stimulation of the actin–myosin complex due to a larger sodium current, causing delayed relaxation of contracted muscle. It may manifest in early childhood and is a multisystem disease. The estimated incidence is 1 in every 8000 births, with an estimated prevalence of between 2.1 and 14.3 cases per 100,000 inhabitants.

Providing a successful anesthesia to patients suffering from Steinert syndrome (MD) constitutes a serious challenge. These difficulties are an implication of multiple disorders which may be related to respiratory, cardiac, and central nervous systems. A myotonic crisis can be induced by numerous factors including hypothermia, shivering, and mechanical or electrical stimulation. In patients with MD, hypersensitivity to anesthetic drugs, especially muscle relaxants and opioids, may complicate postoperative management. Patients may present poor outcomes related to the following complications: loss of airway secondary to medication-induced respiratory depression, aspiration of stomach contents, and sudden death that is usually secondary to cardiac conduction delays and dysrhythmias.

Myotonia is described as muscle contraction (voluntary or otherwise) with abnormal, prolonged relaxation.1-3 Triggers for myotonia include certain medications, potassium, hypothermia, shivering, or any mechanical or electrical stimulus.3-5 Patients also exhibit profound skeletal muscle weakness secondary to muscle degeneration. Dystrophia myotonica (DM, myotonic dystrophy) patients are exquisitely sensitive to the respiratory depressant effects of anesthetic medications.4-6 Postoperative pain control should be managed with non-steroid anti-inflammatory


2. Case description

A 31-year-old male patient (183 cm, 69 kg) was scheduled for laparoscopic operation of cholecystectomy. The rapid sequence intubation guidelines were followed during the induction of general anesthesia. The patient received intravenously: propofol in a dose of 250 mg followed by continuous infusion, rocuronium in a dose of 20 mg, and DEX in a loading dose of 0.6 \( \mu g/kg \) over 10 minutes followed by continuous infusion of dose of 0.2 \( \mu g/kg/hour \). During the intubation, cricoid pressure was maintained. Except hemodynamic parameters, patient’s body temperature was monitored carefully and corrected if needed. No opioids were administered. The anesthesia lasted for 1 hour. All the time patient was warmed by air-blanket. At the end of surgery, 200 mg of sugammadex was administrated to reverse muscle relaxation.

The course of anesthesia and postoperative period were uneventful. The patient exited the operating theatre in a good medical state, with vitals within normal limits and fully regained consciousness. Patient’s consent was obtained for publication. Ethical approval for this case was not necessary because one of the indications for OFA is hypersensitivity to opioids.

This is the first case of opioid-free general anesthesia using DEX in patient with Steinert syndrome described in the medical literature.

The successful use of DEX as adjunct to regional anesthesia was described in a 53-year-old woman with MD for a total abdominal hysterectomy by Yoshino et al.\(^{10}\) Combined spinal and epidural block was used in this patient and DEX was used for sedation during surgery. Airway obstruction was observed after the initial administration of DEX at 2 \( \mu g/kg \), therefore authors concluded that DEX was proved to be useful in this case; however, use of the drug should be carefully started at a low initial dose in patients with MD. We used dose of 0.6 \( \mu g/kg \) and did not observed airway complications.

There are several reports on safe use of DEX for anesthesia in other muscular diseases.\(^{11}\) Rozmiarek et al reported successful use of a combination of DEX and ketamine to provide sedation and analgesia in a 21-year-old patient with Duchenne muscular dystrophy (DMD) undergoing bone marrow aspiration and biopsy.\(^{11}\) Kako et al used 2 different doses of DEX for sedation during muscle biopsy in patients with DMD: 1.0 or 0.5 \( \mu g/kg \) was administered as a loading dose over 3 minutes followed by a continuous infusion of 1.0 or 0.5 \( \mu g/kg/hour \). Ketamine 1 mg/kg was administered along with the DEX loading dose.\(^{12}\)

The regional anesthesia in DM patients is preferred if possible\(^{11,14}\) (thoracic epidural even for cholecystectomy)\(^{13}\); however, in most described cases of general anesthesia of patient with MD, general anesthesia was performed using continuous infusion of propofol.\(^{15,17}\) For analgesia during general anesthesia, remifentanil was used in described cases.\(^{15,17}\) However, remifentanil has been reported to induce hyperalgesia causing difficulties in postoperative pain management, especially after intra-abdominal surgery.\(^{18}\) We decided to perform OFA, in which we have great experience because of bariatric surgery. In myotonic diseases, use of rocuronium and sugammadex was described.\(^{19,20}\)

3. Conclusion

DEX is effective and safe for moderately painful procedures in patients with elevated risk of respiratory and cardiovascular failure. This substance provides adequate analgesia level during surgeries of patients suffering from MD.

References

[1] Barash PG, et al. Clinical Anesthesia. 4th ed.1997;Philadelphia,J.B. Lippincott Company, 32-34, 493–494.
[2] Azar I. The response of patients with neuromuscular disorders to muscle relaxants: a review. Anesthesiology 1984;61:173–87.

[3] Catena V, Del Monte DD, Rubini A, et al. Anesthesia and myotonic dystrophy (Steinert’s syndrome). The role of intravenous anesthesia with propofol, cis-atracurium, and remifentanil. A case report. Minerva Anestesiol 2007;73:475–9.

[4] Ishizawa Y, Yamaguchi H, Dohi S, et al. A serious complication due to gastrointestinal malfunction in a patient with myotonic dystrophy. Anesth Analg 1986;65:1066–8.

[5] Ogawa K, Itanani H, Yoshiyama T, et al. Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy. Can J Anaesth 1993;40:968–70.

[6] Diefenbach C, Lynch J, Abel M, et al. Vecuronium for muscle relaxation in patients with dystrophia myotonica. Anesth Analg 1993;76:872–4.

[7] Moulds RFW, Denborough MA. Myopathies and malignant hyperpyrexia (Correspondence). Br Med J 1974;3:520.

[8] Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Soc Anaesth Soc J 1970;17:293–315.

[9] Kennedy F, Wolf A. Experiments with quinine and prostigmine in treatment of myotonia and myasthenia. Arch Neurol Psychiatry 1937;37:68–74.

[10] Yoshino T, Kanazawa M, Suzuki T. Anesthetic management in a case of myotonic dystrophy with dexametomidine. Masui 2009;58:990–2.

[11] Rozmiarek A, Corridore M, Tobias JD. Dexametomidine-ketamine sedation during bone marrow aspirate and biopsy in a patient with duchenne muscular dystrophy. Saudi J Anaesth 2011;5:219–22.

[12] Kako H, Corridore M, Keen J, et al. Dexametomidine and ketamine sedation for muscle biopsies in patients with Duchenne muscular dystrophy. Paediatr Anaesth 2014;24:851–6.

[13] El-Dawlatly A, Aldohayyan A, Nawaz S, et al. Anesthetic management of a patient with myotonic dystrophy for laparoscopic cholecystectomy—a case report. Middle East J Anaesthesiol 2008;19:1135–40.

[14] Suzuki H, Aoyagi M. Anesthetic management with a laryngeal mask airway for gastrectomy in a patient with myotonic dystrophy. Masui 2003;52:991–5.

[15] Masamune T, Okawa I, Iwashita H, et al. Total intravenous anesthesia with propofol and remifentanil for a patient with myotonic dystrophy. Masui 2009;58:620–2.

[16] Nakashita T, Nishihama M, Hirai A, et al. Successful management of a patient with myotonic dystrophy under total intravenous anesthesia with propofol, remifentanil and rocuronium bromide, combined with epidural anesthesia. Masui 2010;59:1419–22.

[17] Bisinotto FM, Fahri DC, Calçado MS, et al. Anesthesia for video-laparoscopic cholecystectomy in a patient with Steinert disease. Case report and review of the literature. Rev Bras Anestesiol 2010;60:181–91.

[18] Weinbroum AA. Role of anaesthetics and opioids in perioperative hyperalgesia: one step towards familiarisation. Eur J Anaesthesiol 2015;32:230–1.

[19] Kosinova M, Stourac P, Harazim H, et al. Anaesthesia and orphan disease: rocuronium and sugammadex in the anaesthetic management of a parturient with Becker’s myotonia congenital. Eur J Anaesthesiol 2016;33:545–7.

[20] Karwacki Z, Niewiadomski S, Rzaska M. The use of sugammadex for the reversal of vecuronium-induced neuromuscular block following intracranial surgery. Anaesth Intensive Ther 2015;47:297–302. doi: 10.5603/AIT.2015.0042.